Subcutaneous Testosterone Injections for Women: Steady Dosing, Body Benefits, and Integrative Chiropractic Care

Abstract: Testosterone is not only a “male hormone.” Women produce more testosterone than estrogen by weight throughout much of adulthood, and their levels decline with age. The strongest research supports low-dose therapy for postmenopausal women who have distressing low sexual desire. Subcutaneous injections place a small, steady dose into the fat just under the skin so blood levels can return to a normal female range. This article explains how that route works, who may be a candidate, how clinicians monitor the dose, what the body may gain in muscle and bone support, and how integrative chiropractic care in El Paso can work alongside medical oversight to treat the spine, joints, and hormones as one system.

Why Women Need Testosterone, Too

Testosterone is not just a leftover male hormone; women produce it in significant amounts. Across most of adult life, a woman’s ovaries and adrenal glands produce more testosterone than estrogen by mass. That output falls with age and drops further after the ovaries are removed (Davis et al., 2019; Hatzilabrou, 2025).

When levels sit at the low end of a woman’s own range, some women notice a persistent, unwanted loss of desire. That problem has a name: hypoactive sexual desire disorder, or HSDD. Distress is the key. A quiet fade that does not bother her is not the same as a loss that troubles her every day (Davis et al., 2019; Parish et al., 2021).

Pooled randomized trials in thousands of women show that restoring testosterone into the normal premenopausal range can improve desire, arousal, orgasm, pleasure, and satisfaction, and can lower sexual distress. The gains are real and consistent, but they are moderate, not magic, and a strong placebo response is part of the picture (Islam et al., 2019; Hatzilabrou, 2025).

What Subcutaneous Injections Actually Do

A subcutaneous (SubQ) injection delivers medicine into the fatty layer just under the skin, not deep into muscle. Typical sites are the abdomen or outer thigh. The needle is short and thin. The oil-based testosterone (often testosterone cypionate) then seeps out slowly, which can keep blood levels steadier than a large intramuscular shot (FOLX Health, n.d.; Hone Health, 2024).

Think of it as a small, measured drip rather than a flood. Women need far less than men—often about one-tenth of a typical male dose. Clinics that use weekly SubQ cypionate often start in the low single-digit to low double-digit milligram range and then adjust to a lab result, not to a feeling (Highland Longevity, n.d.; Hone Health Help Center, n.d.).

Important facts about the route:

• Most high-quality trials in women used patches, creams, or gels, not weekly shots (Hatzilabrou, 2025).
• One older implant study in women was positive for desire and bone density, but fixed pellets can overshoot the female range and cannot be turned down once placed (Hatzilabrou, 2025).
• There is no published milligram “conversion chart” from a 300 microgram patch to a SubQ syringe. The honest method is to dose to a measured blood level (Davis et al., 2019; Hatzilabrou, 2025).
• No testosterone product is FDA-approved for women in the United States. Use is off-label and requires informed consent (Cedars-Sinai, n.d.; Parish et al., 2021).

Some compounding programs now offer low-concentration, prefilled single-dose syringes of testosterone cypionate in MCT oil for SubQ use. These products aim to make a tiny dose easier to administer. They do not change the rules: the clinician must still keep blood levels within the female physiologic band and must not treat a syringe as proof that shots have the same trial record as patches (Hatzilabrou, 2025; Medivant Health, n.d.).

The Target Is a Narrow Band, Not “More Is Better”

A healthy young woman typically has a total testosterone level of about 15 to 46 ng/dL. That is a sliver of the male range. The job of therapy is to land inside that band and stay there (Hatzilabrou, 2025; Braunstein et al., 2011).

Pushing past the ceiling does not add extra desire. It shows up as acne, extra facial hair, scalp thinning, voice change, and other androgen effects (Islam et al., 2019; Parish et al., 2021).

A practical path looks like this:

• Confirm HSDD with real distress after other causes are checked.
• Draw a baseline total testosterone with a sensitive LC-MS/MS test, not a routine immunoassay built for men (Rosner et al., 2007).
• Start low.
• Recheck the level and symptoms at about 8 to 12 weeks.
• Assess benefit at 3 to 6 months. If distressing low desire has not improved, stop rather than climb (Davis et al., 2019; Parish et al., 2021).

Baseline testosterone does not diagnose HSDD. It is a safety tool once treatment starts (Hatzilabrou, 2025).

What the Body May Gain Beyond Desire

Sexual function is the outcome with the firmest trial support. Other claims need a quieter voice.

Muscle and strength. Testosterone helps muscle protein building in both sexes. Some women report better lean mass and training response when their levels return to a mid-physiologic range. Large pooled trial data in women have not shown a robust body-composition effect at the low doses used for HSDD, so frame this as possible support, not a guarantee (Islam et al., 2019; Hatzilabrou, 2025).

Bone. One small two-year implant trial found faster gains in spine, hip, and total-body density when testosterone was added to estradiol. Guidelines still do not list bone as an approved reason to prescribe it, partly because the study was small and its primary design was not to prevent fractures (Davis et al., 1995; Wierman et al., 2014).

Energy and mood. Early and smaller studies sometimes showed better well-being. Dedicated trials and systematic reviews have been mixed or null for mood, fatigue, and cognition. Societies do not endorse testosterone as a general menopause tonic (Islam et al., 2019; Dichtel et al., 2020; Cedars-Sinai, n.d.).

Red blood cells. Testosterone can raise red-cell production. That is a monitoring issue at higher exposure, not a reason to treat ordinary anemia in women (Hatzilabrou, 2025).

For the spine and joints, even a modest hold on muscle and bone matters. Stronger hip and core muscles help the pelvis stay level. Better bone quality supports the vertebrae that a chiropractor adjusts. After a car crash or a work injury, patients who can train without crashing energy often stay in rehab longer (Jimenez, n.d.-a).

Safety, Side Effects, and the Long View

Short- and medium-term data at physiologic doses are generally reassuring for the day-to-day effects clinicians watch: acne, extra hair, and oily skin. Those effects are usually dose-related and often fade if the dose is cut (Islam et al., 2019; Nachtigall et al., 2011).

What is missing is the long view. Adequately powered trials have not settled cardiovascular and breast outcomes over many years. That gap—not a proven harm signal—is a main reason no female product has been approved (Hatzilabrou, 2025; Cedars-Sinai, n.d.).

Therapy is not for pregnancy, breastfeeding, or people trying to conceive. Women with high baseline heart or breast-cancer risk need an especially clear shared decision (Hone Health Help Center, n.d.; Parish et al., 2021).

How Integrative Chiropractic Care Fits

Hormones don’t exist apart from the skeleton. Low energy, weaker muscles, and slower recovery make spinal joints stiffer and make rehab after an auto accident harder. Integrative care treats that loop instead of just giving a woman a syringe or an adjustment.

At Injury Medical Clinic PA in El Paso, Texas (11860 Vista Del Sol, Suite 128), we build care as a team. Dr. Alexander Jimenez, DC, APRN, FNP-BC, CCST, CFMP, IFMCP, ATN, is dual-licensed as a chiropractor and board-certified family nurse practitioner. His clinical writing stresses that female testosterone use is not a copy of male replacement: the best randomized evidence is still transdermal; SubQ use in women is an individualized off-label choice, and the goal is a physiologic range with a stop rule if desire does not improve (Jimenez, n.d.-b).

Dr. Maria Guadalupe Cardenas, MD, is his physician, board-certified in internal medicine (NPI #1164426749, Texas MD License #J2933), with more than 40 years of experience as an internist. She serves as medical director and collaborative physician. In this model, the internist provides medical direction, reviews labs and overall health, and helps keep advanced or off-label therapies within safe bounds. The chiropractor restores joint motion, posture, and neuromuscular control. Functional medicine looks at sleep, gut health, thyroid, iron, and medications such as SSRIs that can blunt desire on their own. Personal injury and rehabilitation services rebuild strength after crashes, falls, and sports injuries, so a hormone plan isn’t asked to do the work of a weak core or an unhealed disc (Jimenez, n.d.-a).

That mix is common in integrated injury clinics: an MD directs the medical lane while a DC treats the mechanical lane. For a woman on low-dose testosterone, the practical payoff is simple. When the muscles around the spine hold better, adjustments last longer. When bone and lean mass improve, fall risk and “I feel fragile” complaints may ease. If pain and sleep improve, desire often has a clearer path—without pretending testosterone is a cure for every menopausal complaint.

A Clear Path Forward

Testosterone therapy in women is neither a wellness trend nor a male protocol scaled down by guesswork. It is a narrow, evidence-backed option for postmenopausal HSDD with distress, given at a female physiologic dose, watched with the right lab, and stopped if it does not help.

Subcutaneous injections can deliver that small, steady dose into the fat under the skin. They ask for discipline: start low, measure, stay inside the range, and pair the hormone with the rest of the care—local vaginal treatment when dryness is the real problem, medication review when an antidepressant is the real problem, and hands-on musculoskeletal care when the spine and hips cannot carry the load.

In El Paso, that whole-person path is the point of the collaboration between Dr. Cardenas’s internal medicine oversight and Dr. Jimenez’s chiropractic, functional medicine, and injury rehab work. The hormone is only one tool. The goal is a woman who can move, recover, and feel like herself again.

---

References

Braunstein, G. D., Reitz, R. E., Buch, A., Schaefer, D., & Caulfield, M. P. (2011). Testosterone reference ranges in normally cycling healthy premenopausal women. The Journal of Sexual Medicine, 8(10), 2924–2934.

Cedars-Sinai. (n.d.). Testosterone therapy for women.

Davis, S. R., Baber, R., Panay, N., Bitzer, J., Perez, S. C., Nappi, R. E., Nijland, E., Simon, J., Vignozzi, L., & Wierman, M. E. (2019). Global consensus position statement on the use of testosterone therapy for women. The Journal of Clinical Endocrinology & Metabolism, 104(10), 4660–4666.

Davis, S. R., McCloud, P., Strauss, B. J., & Burger, H. (1995). Testosterone enhances estradiol’s effects on postmenopausal bone density and sexuality. Maturitas, 21(3), 227–236.

Dichtel, L. E., Carpenter, L. L., Nyer, M., Mischoulon, D., Kim, S., Cusin, C., Pedrelli, P., Fisher, L., Papakostas, G. I., & Fava, M. (2020). Low-dose testosterone augmentation for antidepressant-resistant major depressive disorder in women: An 8-week randomized placebo-controlled study. American Journal of Psychiatry, 177(10), 965–973.

FOLX Health. (n.d.). HRT subcutaneous vs. intramuscular injections.

Hatzilabrou, T. A. (2025). Testosterone therapy in women [White paper]. Worldborne Medical / Medivant Healthcare.

Highland Longevity. (n.d.). Women’s testosterone dosing guide.

Hone Health. (2024). Injectable testosterone cypionate for women.

Hone Health Help Center. (n.d.). Testosterone cypionate injection for women: Risks & benefits.

Islam, R. M., Bell, R. J., Green, S., Page, M. J., & Davis, S. R. (2019). Safety and efficacy of testosterone for women: A systematic review and meta-analysis of randomised controlled trial data. The Lancet Diabetes & Endocrinology, 7(10), 754–766.

Jimenez, A. (n.d.-a). Injury specialists. Injury Medical Clinic PA.

Jimenez, A. (n.d.-b). Subcutaneous testosterone for hormone balance therapy guide. Injury Medical Clinic PA.

Medivant Health. (n.d.). Andrenyx.

Nachtigall, L., Casson, P., Lucas, J., Schofield, V., Melson, C., & Simon, J. A. (2011). Safety and tolerability of testosterone patch therapy for up to 4 years in surgically menopausal women receiving oral or transdermal oestrogen. Gynecological Endocrinology, 27(1), 39–48.

Parish, S. J., Simon, J. A., Davis, S. R., Giraldi, A., Goldstein, I., Goldstein, S. W., Kim, N. N., Kingsberg, S. A., Morgentaler, A., Nappi, R. E., Park, K., Stuenkel, C. A., Traish, A. M., & Vignozzi, L. (2021). International Society for the Study of Women’s Sexual Health clinical practice guideline for the use of systemic testosterone for hypoactive sexual desire disorder in women. The Journal of Sexual Medicine, 18(5), 849–867.

Rosner, W., Auchus, R. J., Azziz, R., Sluss, P. M., & Raff, H. (2007). Utility, limitations, and pitfalls in measuring testosterone: An Endocrine Society position statement. The Journal of Clinical Endocrinology & Metabolism, 92(2), 405–413.

Wierman, M. E., Arlt, W., Basson, R., Davis, S. R., Miller, K. K., Murad, M. H., Rosner, W., & Santoro, N. (2014). Androgen therapy in women: A reappraisal. An Endocrine Society clinical practice guideline. The Journal of Clinical Endocrinology & Metabolism, 99(10), 3489–3510.